IQVIA Holdings Inc. $IQV Shares Acquired by Jump Financial LLC

Key Points

• Jump Financial LLC has significantly increased its stake in IQVIA Holdings Inc. by 717.6%, owning 59,200 shares valued at approximately $10.4 million as of the latest SEC filing.
• IQVIA reported a quarterly earnings per share (EPS) of $2.81, surpassing analysts' estimates and showing a revenue increase of 5.3% year-over-year to $4.02 billion.
• Recent analyst ratings for IQVIA show a consensus of "Moderate Buy," with target prices ranging from $177.00 to $235.00, reflecting positive expectations for the company's growth.

Jump Financial LLC raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 717.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 59,200 shares of the medical research company's stock after purchasing an additional 51,959 shares during the quarter. Jump Financial LLC's holdings in IQVIA were worth $10,437,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of the stock. American National Bank & Trust purchased a new stake in shares of IQVIA in the 1st quarter valued at $26,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of IQVIA by 436.7% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company's stock valued at $28,000 after acquiring an additional 131 shares during the last quarter. Golden State Wealth Management LLC boosted its holdings in shares of IQVIA by 295.5% in the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after acquiring an additional 130 shares during the last quarter. AllSquare Wealth Management LLC purchased a new stake in shares of IQVIA in the 1st quarter valued at $33,000. Finally, ST Germain D J Co. Inc. boosted its holdings in shares of IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after acquiring an additional 76 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Insiders Place Their Bets

In other IQVIA news, insider Eric Sherbet sold 5,800 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Keriann Cherofsky sold 549 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on IQV. Cowen reissued a "buy" rating on shares of IQVIA in a report on Wednesday, July 23rd. JPMorgan Chase & Co. lowered their price target on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a report on Monday, May 19th. Mizuho lifted their target price on shares of IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Truist Financial lifted their target price on shares of IQVIA from $209.00 to $235.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Finally, Robert W. Baird raised their price target on shares of IQVIA from $159.00 to $196.00 and gave the stock a "neutral" rating in a research note on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $228.62.

IQVIA Stock Performance

IQV stock traded down $0.07 on Thursday, hitting $188.73. The company's stock had a trading volume of 1,152,415 shares, compared to its average volume of 1,946,076. The firm has a 50 day moving average of $175.64 and a two-hundred day moving average of $168.11. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The stock has a market cap of $32.08 billion, a price-to-earnings ratio of 27.31, a price-to-earnings-growth ratio of 2.06 and a beta of 1.30. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.45.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, beating the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. IQVIA's revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.64 EPS. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.